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Abstract
Background: Bacteria are suspected players in the pathogenesis of chronic rhinosinusitis (CRS), yet their exact role
is not understood. We investigated the effect of planktonic and biofilm of staphylococcus aureus (SA) and
Pseudomonas aeruginosa (PA) on the mucosa of CRS patients with gram-positive and gram-negative infections by
measuring the levels of IL-6 and RANTES, a chemokine with activity on eosinophils and T lymphocytes.
Methods: Ethmoid mucosa of six CRS patients with gram-positive bacteria on culture and five with gram-negative
bacteria were compared to ethmoid mucosa of 8 control patients. The tissue explants were stimulated with SA and
PA extracts in planktonic and biofilm form for 6 hours, then RANTES levels were measured by ELISA.
Results: Compared to the control group, CRS patients with gram-negative predominance demonstrated a
significantly higher level of RANTES expression in response to all forms of bacterial stimuli (P-value <0.05). Patients
with gram-positive predominance showed a higher level of RANTES compere to control group, however, this
difference was not significant (P-value >0.05).
Conclusions: The mucosa of CRS patients with gram-negative infections has a heightened innate immune
response compared to controls and patients with gram-positive infections. It is possible that this response leads to
the pathological eosinophilic inflammation seen in CRS.
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Background
Chronic rhinosinusitis (CRS) is defined as an inflammatory
condition of the paranasal sinuses and nasal passages that
persists for a minimum of 8 to 12 weeks [1, 2]. The preva-
lence rate among the general Canadian population is esti-
mated to be 5%. There is general agreement that no one
causative factor fully explains or adequately accounts for
the pathologic manifestations and clinical heterogeneity of
rhinosinusitis [3, 4].
CRS can be divided based on the presence of nasal
polyps into: CRS with nasal polyp (CRSwNP) and with-
out nasal polyp (CRSsNP). It was thought that the
CRSwNP was the endpoint of the CRSsNP, however, this
hypothesis is no longer accepted [5]. The two categories
are completely different entities based on clinical presen-
tation, distinct inflammatory pathways, cytokine profiles,
and different tissue remodeling [5]. TH2 lymphocyte is
the predominant type of lymphocyte in CRSwNP that
results in recruitment of eosinophil, whereas CRSsNP is
characterized by higher levels of neutrophil because the
predominant type of lymphocyte is TH1 lymphocyte.
Bacteria are suspected players in the pathogenesis of
chronic rhinosinusitis (CRS), yet their exact role is not
understood. Bacterial infection is one of the most im-
portant causative factors in CRS. Another study suggests
that bacteria and fungi are more likely to be disease
modifiers rather than primary causative agents in predis-
posed individuals [6].
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Gram-positive bacteria are the most common cause of
infection in CRS patients. Staphylococcus bacteria are the
predominant cause type of infection in gram-positive pa-
tients; whereas in gram-negative infections, P.aeruginosa
is the most common cause of infection. In a retrospective
study done by Wormald et al., S.aureus was found to be
the most common isolated bacteria in CRS patients (35%),
followed by P.aeruginosa (9%), Haemophilus spp (7%) and
S. pneumonia (5%) [7].
Bacteria exist in two forms in the sinus - planktonic
and biofilm forms. It has been estimated that more the
99% of bacteria exist in biofilm form [8]. A biofilm is
defined as “a microbially derived sessile community
characterized by cells that are irreversibly attached to a
substratum or interface or to each other, are embedded
in a matrix of extracellular polymeric substances that
they have produced, and exhibit an altered phenotype
with respect to growth rate and gene transcription” [9].
A significant number of studies identified biofilms in the
mucosa of CRS as ranging from 25% to 92% [8].
Innate immunity is the first line of defense against
infection. Unlike adaptive immunity, the innate immune
system lacks specificity. However, innate immune effector
cells recognize the pathogens through their pathogen-
associated molecular patterns (PAMP). PAMPs have sev-
eral important features relevant to innate immunity; they
are found only in the pathogen and never in the host cell,
and an entire class of pathogens shares the same PAMPs.
For example, gram-negative bacteria all have lipopolysac-
charide (LPS) as a cell wall component and gram-positive
bacteria all have lipoteichoic acid (LTA) [10].
IL-6 is the key cytokine responsible for the transition
from innate immunity to adaptive immunity [11]. In
Cantero et al.’s study, IL-6 was higher in S.aureus biofilm
treated mucosa compared to the control group [12].
Regulated on Activation, Normal T cell Expressed and
Secreted (RANTES) is a member of the CC chemokines
family and a well-known major eosinophil attractant [13,
14]. Beck et al. demonstrated the presence of RANTES
immunoactivitiy in the nasal polyp biopsies [14]. Teran
et al. reported that RANTES is released into the super-
natant of the cultured nasal polyp tissue [15]. Immuno-
histological studies showed that RANTES is present on
the nasal epithelium of patients with nasal polyps [14].
Our objective was to investigate the innate immune
response of CRS patients with gram-positive and gram-
negative infections to planktonic and biofilms of staphylo-
coccus aureus (SA) and Pseudomonas aeruginosa (PA) by
measuring the level of RANTES, and IL-6. The working
hypothesis of this research was that CRS patients with
different types of predominant infections have different
innate immune responses to bacteria at the mucosal level.
These altered immune responses may explain in part the
bacterial species predominance within the sinuses, the
severity of the disease phenotype, and the general
susceptibility to disease development.
Methods
Study design and populations
A case-controlled prospective study was undertaken.
Eleven patients with CRS and eight control subjects that
had undergone a transsphenoidal resection of a pituitary
tumor were included in this study. The research proto-
col was approved by the McGill University Health
Centre ethics committee and informed consent was
obtained from all subjects. A Nonparametric (Mann–
Whitney) tests with Dunn’s multiple comparisons test
were used for the statistical analysis using GraphPad
Prism (version 7.0).
Patients with CRS were selected according to the
definition of the American clinical practice guidelines
for acute and chronic rhinosinusitis [2]. Patients were
recruited following inclusion criteria, 1) Documented
diagnosis of bilateral CRS, 2) Documented positive cul-
tures for either gram-negative bacteria on at least two
separate occasions or gram-positive bacteria on at least
two separate occasions, 3) Eighteen to sixty-five years of
age, 4) Documented failed medical treatment of CRS,
and 5) Patients off antibiotics and systematic/intranasal
corticosteroid for at least 1 month prior to surgery. Patients
with 1) Documented diagnosis of fungal sinusitis, 2) Docu-
mented positive fungal culture, 3) Diagnosed Crohn’s dis-
ease, 4) Diagnosed immotile cilia syndrome, 5) Diagnosed
cystic fibrosis or 6) Diagnosed immunodeficiency syndrome
were excluded from this study.
CRS patients were further divided based on the presence
or absence of nasal polyps into CRS with nasal polyps
(CRSwNP) and CRS without nasal polyp (CRSsNP); the
diagnosis was based on the American clinical practice
guidelines for acute and chronic rhinosinusitis [2].
Patients who underwent skull base surgery were used as a
control in this study. Preoperative paranasal sinus CT
scans were used to access the severity of the disease using
the Lund–Mackay scoring system.
Sample collection
Multiple nasal mucosa biopsies were taken mainly from
the ethmoid and sphenoid sinuses. Nasal swabs were
taken before harvesting the nasal tissue and before
administrating the prophylactic antibiotics. The samples
were placed immediately on ice and transferred to the
Meakins-Christie laboratories (the Research Institute of
the McGill University Health Centre). Specimens were
washed three times with ice-cold phosphate-buffered
saline (PSB) before being cut into pieces of equal weight.
Each biopsy piece was distributed to one of 6 experi-
mental groups in 12-wells tissue culture plates and
cultured in 75% Dulbecco’s modified Eagle’s medium/
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25% Hanks’ buffer solution (100 U/mL penicillin G and
100 μg/mL streptomycin) without serum for 72 h. Every
24 h, the medium was refreshed.
Sample stimulation
On the third day, biopsy pieces were left unstimulated,
as control, or were stimulated for 6 hours in duplicate at
37 °C using planktonic Staphylococcus aureus (PSA),
biofilm staphylococcus aureus (BSA), planktonic Pseudo-
monas aeruginosa (PCF) or biofilm Pseudomonas aeru-
ginosa (BCF). Then the media and the nasal tissue were
snap-frozen and stored at −80 °C until further analysis.
The duration of stimulations was based on previous
study that showed; 6 hours stimulations is sufficient time
to get expression for both mRNA and proteins [16].
Bacterial strain and materials
The Pseudomonas aeruginosa strain used in this study was
PACF508. This is a stable mucoid clinical isolate from the
sputum of a patient with cystic fibrosis (Hôpital Sainte-
Justine, Montréal, Canada) [17]. Regarding the Staphylo-
coccus aureus, the strain was purchased from American
Type Culture Collection (ATCC, Manassas, VA).
Diffusible material preparation
Planktonic S. Aureus and P.aeruginosa Diffusible
material from planktonic S.aureus (PSA) was produced
in 4% peptone (Fischer scientific, Pittsburgh, PA). S.aureus
was grown in 5 mL of desired media in 12 mL test tubes
at 37 °C for 72 h with shaking at 250 RPM. Following this
growth, the culture was centrifuged at 2100 X g for
20 min to pellet cells. The supernatant was collected and
filtered through a 0.22 μM filter (Millipore), aliquoted and
stored at −20 °C for use within the month or −80 °C for
longer storage. Prior to use, the total protein content was
determined via a standard Bradford assay. Similar protocol
was used to produce the P. aeruginosa diffusible material.
Biofilm S. Aureus and P.aeruginosa Static PsaDM and
S.aureus biofilm were prepared in peptone or SCFM as
follows: ~5 × 107 log phase cells were used to seed each
6 mm polystyrene tissue culture wells (Falcon, Franklin
Lakes, NJ). After 3 hours of initial attachment, the
media was removed, replaced with fresh media, and the
attached bacteria were incubated statically at 37 °C for
an additional 24 h. After this time, the attached cells
were scraped off the plate and were combined with the
cell suspension within the well. Bacteria were centri-
fuged at 2100 X g for 30 min and the supernatant was
collected and filtered through a 0.22 μm filter. Total
protein of filtrates was measured by the Bradford
method. Prior to use, bacterial filtrates were heat
inactivated at 95 °C for 10 min (to inactivate proteases)
and allowed to cool to room temperature.
Elisa
Human CCL5/RANTES (DY278) DuoSet ELISA kit was
purchased from R&D Systems (MN, USA). A human IL-6
ELISA kit (900-K16) was purchased from PeproTech (NJ,
USA). All primers were ordered from Invitrogen (Carlsbad,
CA.). Berube et.al. [18] 100 μL of supernatant collected
after cell stimulation was directly used for RANTES quan-
tification or diluted 1:50 for IL-6 quantification per the
manufacturer’s protocol. (Additional files 1 and 2).
Results
A total of eight control and 11 patients were recruited. Of
the eleven, six had predominant gram-positive infections,
three of which had CRSwNP, and five had gram-negative
infections, three of which had CRSwNP. Baseline charac-
teristics of patients population is shown in Table 1. Four
patients had previous sinus surgery, two patients with
gram-positive infections and two patients with gram-
negative infections. All patients have no allergy.
Rantes
Controls vs. patients
A strong RANTES production was observed in all CRS
patients. The difference between the levels of RANTES se-
creted by the mucosa in response to all bacterial stimuli,
in control and in CRS patients was statistically significant
as shown in Fig. 1. Moreover, the unstimulated sample
from CRS patients showed a significant amount of
RANTES when compared to the unstimulated sample
from the control group (P = 0.005). Comparison of
RANTES production in response to PSA stimuli between
control and CRS patients revealed a significantly higher
level of RANTES (P = 0.02). Similarly, stimulated nasal
mucosa taken from CRS patients released a significantly
higher level of RANTES compared to stimulated nasal
mucosa samples taken from control patients in response
to BSA (P = 0.02), PCF (P = 0.02) and BCF (P = 0.02). The
highest level of RANTES was seen when the samples from
CRS were stimulated by PSA (160.32 ± 39.65).
Table 1 Baseline characteristics of patients population
Control Case
Gram Positive Gram Negative
No. 8 6 5
Mean Age 58.5 43.5 56.2
Gender (M:F) 4:4 4:2 3:2
Lund–Mackay score 0 13.6 16
CRSwNP 3 3
CRSsNP 3 2
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Control vs. gram-positive vs. gram-negative
A subgroup analysis showed that mucosal samples taken
from CRS patients with predominant gram-negative
infections had a stronger production of RANTES in
response to all types of stimuli compared to control and
CRS patients with predominant gram-positive infections,
(Fig. 2). In the case of unstimulated samples, CRS
patients with predominant gram-negative infections pro-
duced higher level of RANTES compared to control pa-
tients and CRS patients with predominant gram-positive
infections and the difference between the control group
and gram-negative patients’ group was statistically
significant, P = 0.01, however, no statically significant
difference was observed between gram-positive patients’
when compared to gram-negative patients’ group. The
strongest production of RANTES was observed when
the mucosal samples taken from CRS patients with
predominant gram-negative infections were stimulated
with PSA; and when this result was compared to control
group, the difference was statistically significant, P = 0.03.
However, when the RANTES level produced in response
to PSA stimulation in CRS patients with predominant
gram-negative infections was compared to CRS patients
with predominant gram-positive infections, the result was
statistically insignificant. Stimulation by BSA also induced
RANTES production to a higher level in CRS patients with
gram-negative infections compared to controls and to CRS
patients with predominant gram-positive infections and
the difference was only statistically significant, P = 0.0053,
when the non-CRS group was compared to CRS patients
with predominant gram-negative infections. Moreover,
Planktonic form of P.aeruginosa significantly induced
higher RANTES production from the mucosal samples
harvested from CRS patients with predominant gram-
negative infections compared to mucosa from patients with
predominant gram-positive and non-CRS patients, with a
P-value = 0.02. BCF stimulation induced similar results, i.e.
the highest production of RANTES was observed with
gram-negative mucosa followed by gram-positive mucosa
and control (P = 0.03).
CRSwNP vs. CRSsNP
Although patients with CRSwNP showed a higher level
of RANTES production compared to CRSsNP in re-
sponse to PSA, BSA and PCF, none of those differences
were statistically significant (P = 0.51, 0.32 and 0.69,
respectively). In unstimulated conditions, no statically
significant differences were observed between CRSwNP
and CRSsNP. Similarly, stimulated mucosa by BCF did not
show any significant difference in RANTES production
between CRSwNP and CRSsNP, (Fig. 3).
Fig. 1 Comparison of RANTES level between control subjects and CRS
patients with different type of bacterial stimulation. The RANTES levels
were significantly higher in CRS patients compared to controls in all
type of stimulations. Untreated UT; Planktonic Staphylococcus
Aureus PSA; Biofilm Staphylococcus Aureus BSA; Planktonic
Pseudomonas aeruginosa PCF; Biofilm Pseudomonas aeruginosa BCF
Fig. 2 Difference of RANTES level in CRS with gram-positive and negative
infections compared to control group in response to different types of
bacterial stimulation. CRS patients with Gram-negative infection have
a significantly higher level of RANTES compared to patients with
predominant gram-positive infection and to control subjects.
Untreated UT; Planktonic Staphylococcus Aureus PSA; Biofilm
Staphylococcus Aureus BSA; Planktonic Pseudomonas aeruginosa
PCF; Biofilm Pseudomonas aeruginosa BCF
Fig. 3 Difference of RANTES level in CRSwNP and CRSsNP in response
to different types of bacterial stimulation. CRS patients with nasal
polyps have a significantly higher level of RANTES compared to
patients without nasal polyps. Untreated UT; Planktonic
Staphylococcus Aureus PSA; Biofilm Staphylococcus Aureus BSA;
Planktonic Pseudomonas aeruginosa PCF; Biofilm Pseudomonas
aeruginosa BCF; Chronic Rhinosinusitis with nasal polyps CRSwNP;
Chronic Rhinosinusitis without nasal polyps CRSsNP
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IL-6
Controls vs. patients
No significant differences were observed in IL-6 produc-
tion from samples taken from CRS patients in response to
various stimuli compared to the control group; however,
there was a trend for higher IL-6 production among CRS
patients. The difference between the production of IL-6
from the unstimulated samples in the case group and the
control was statistically insignificant, P = 0.14. Addition-
ally, stimulation by PSA did not show a statistically signifi-
cant difference (P = 0.17) in IL-6 production in CRS
patients compared to controls. Similarly, no significant
differences were observed when the IL-6 levels produced
by the control group in response to all types of bacterial
stimulation were compared to the CRS group, namely:
BSA (P = 0.19), PCF (P = 0.11) and BCF, (with P-value
equal 0.19, 0.11 and 0.26 respectively), (Fig. 4).
Control vs. gram-positive vs. gram-negative
In the unstimulated samples, the difference between
CRS patients with predominant gram-positive infections
compared to control and to CRS patients with predom-
inant gram-negative infections were insignificant. How-
ever, the trend observed was of a higher production of
IL-6 in patients with gram-positive infections compared
to control and to CRS patients with predominant gram-
negative infections (Fig. 5). In the case of PSA stimula-
tion, CRS patients with predominant gram-negative in-
fections produced higher levels of IL-6 compared to
control patients and to CRS patients with predominant
gram-positive infections; the difference between these
groups was statistically significant. Stimulation by BSA
did not show statistically significant differences in IL-6
production between the three groups. Moreover, BSA
induced almost equal amounts of IL-6 production in
CRS patients with gram-negative infections and patients
with predominant gram-positive infections and controls.
No significant difference was observed when IL-6 pro-
duction following PCF stimulation of mucosa from
gram-negative infected patients compared to the gram-
positive group and to the control group. Moreover, mu-
cosal stimulation with biofilm form of P.aeruginosa did
not show statistically significant difference in IL-6 pro-
duction; however, higher level of IL-6 was observed in
patients with predominant gram-negative infections and
in patients with gram-positive infections compared to
non-CRS patients, (Fig. 5).
CRSwNP vs. CRSsNP
When the level of IL-6 production in response to PSA
was compared in CRSwNP to the level in CRSsNP the
results were statistically insignificant. Similar results were
observed in response to BCF stimulation. In unstimulated
conditions, no differences were observed between
CRSwNP and CRSsNP. Similarly, stimulated mucosa by
BSA and PCF did not show any differences in IL-6
production between CRSwNP and CRSsNP, (Fig. 6).
Discussion
The hypothesis of this study is that CRS patients with
different types of predominant infections have different
immune responses to bacteria at the mucosal level. The
role of bacteria has been given a lot of attention in the
medical literature, particularly in regards to their effect
on alteration of the host immune system. Recently, an
increasing amount of rhinology literature has focused on
bacteria not as a primary causative factor of CRS, but
rather as a disease modifier. To our knowledge, this is
the first study to differentiate CRS based on their
Fig. 4 Comparison of IL-6 level between control subjects and CRS
patents with different type of bacterial stimulation. The IL-6 levels were
higher in CRS patients compared to controls in all type of stimulations,
however, the difference was statistically insignificant. Untreated UT;
Planktonic Staphylococcus Aureus PSA; Biofilm Staphylococcus Aureus
BSA; Planktonic Pseudomonas aeruginosa PCF; Biofilm Pseudomonas
aeruginosa BCF
Fig. 5 Difference of IL-6 level in CRS with gram-positive and negative
infections compared to control group in response to different types of
bacterial stimulation. CRS patients with Gram-negative infection have
no significant difference in IL-6 level compared to patients with
predominant gram-positive infection and to control subjects.
Untreated UT; Planktonic Staphylococcus Aureus PSA; Biofilm
Staphylococcus Aureus BSA; Planktonic Pseudomonas aeruginosa
PCF; Biofilm Pseudomonas aeruginosa BCF
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predominant bacteria found in the sinuses while investi-
gating relevant innate immune responses.
Eosinophils play an important role in the pathogenesis
of CRS [19]. Studies have shown that an increased level
of tissue eosinophilia is correlated with the severity of
the disease and with the risk of disease recurrence [19].
RANTES is a potent chemoattractant for eosinophils
[14]. In vivo studies have proven that RANTES induces
symptomatic inflammatory response by causing recruit-
ment of eosinophils [20]. In our study, we successfully
demonstrated that nasal mucosa taken from CRS
patients were primed to produce RANTES to a higher
level compared to non-CRS subjects. Cavallari et al. ob-
served that polyps taken from CRS patients showed a
higher level of RANTES gene expression compared to
the control group [21]. Lane et al. also detected a higher
level of RANTES expression in patients with CRS
(CRSwNP and CRSsNP) compared to normal nasal mu-
cosa [22]. However, in the present study we did not
measure the level of the tissue eosinophil. Interestingly,
a higher level of RANTES production was observed in
CRS compared to the control group, even without any
stimulation. This could be explained by the fact that
there are already chronic inflammation processes in CRS
patients and subsequent bacterial stimulation will aug-
ment this process and result in increased production of
RANTES. Also, patient with predominant gram-positive
infections did not show a significant increase in
RANTES production compare to patients with predom-
inant gram-positive infections. This could be explained
by the fact that gram negative bacteria are particularly
virulent, hence they elicit more immune response.
Eosinophils have been associated with host protection
from parasitic infections [23, 24]. This type of infection
elicits a Th2 immune response which results in IL-5 pro-
duction, an essential cytokine for eosinophil differentiation
[23]. In the present study, we observed a higher level of
RANTES production, an essential eosinophilic chemotac-
tic, in CRS patients with predominant gram-negative
infections, suggesting that perhaps CRS represents a
pathological misrecognition of gram-negative bacteria as
parasitic which then results in an abnormal eosinophilic
response.
Within the clinical realm of sinus disease, gram-
negative bacteria are particularly virulent and often are
associated with medically and surgically recalcitrant in-
flammation. Patients with predominant gram-negative
infections are very difficult to treat and have a poor
response to sinus surgery. Batcharyya et.al showed that
14.8% of post-ESS patients had persistent gram-negative
infections; with P.aeruginosa being the most common
isolated bacteria [25]. Similar results were observed in
the Nadal et al. study that found that gram-negative in-
fections were present in 27% of cultures (16% are P.aeru-
ginosa). Moreover, patients with prior surgeries had a
significantly higher level of gram-negative isolate (30%)
compared to patients with no prior ESS (9.5%) [26]. In
our study, we were able to show that patients with
chronic gram-negative infections had a higher response
to bacterial stimulation in the form of production of
RANTES compared to control and patients with gram-
positive infections. This finding is consistent with the
clinical picture of gram-negative patients, who often
have very severe disease and require multiple surgeries.
Moreover, this finding suggests that bacterial products
were able to stimulate the innate immune responses in pa-
tients with chronic gram-negative infections compared to
patients with gram-positive infections. However, the exact
reason why gram-negative patients behave differently is
not understood though we could speculate that patients
with chronic gram-negative infections have a more severe
underlying inflammatory process compared to gram-
positive CRS patients, and that this difference has an effect
on the innate immune response and gene expression.
CRS is a heterogonous disease, with a wide variety of
disease severity and phenotypes; one accepted way to
subcategorize CRS is based on the presence or absence
of nasal polyps into CRSwNP and CRSsNP. A study by
Zhang et al. suggested that they have different and dis-
tinct pathophysiology leading to inflammation [27].
However, in our study we did not find a statistically
significant difference in either RANTES or IL-6 produc-
tion between CRSwNP and CRSsNP patients when the
tissue explant was subjected to different types of bacter-
ial stimulation, suggesting that those two cytokines
could be equally produced between the two spectrums
of the disease.
Biofilms have gained a lot of attention in rhinology
literature in the last few decades. Studies estimated the
presence of biofilms in the sinus of CRS patients to be
Fig. 6 Difference of IL-6 level in CRSwNP and CRSsNP in response to
different types of bacterial stimulation. CRS patients with nasal polyps
have similar level of IL-6 compared to patients without nasal polyps.
Untreated UT; Planktonic Staphylococcus Aureus PSA; Biofilm
Staphylococcus Aureus BSA; Planktonic Pseudomonas aeruginosa PCF;
Biofilm Pseudomonas aeruginosa BCF; Chronic Rhinosinusitis with nasal
polyps CRSwNP; Chronic Rhinosinusitis without nasal polyps CRSsNP
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between 70% and 80% [28, 29]. Patients with biofilms
usually presented with more severe symptoms and worse
radiological and endoscopy scores compared to biofilm
negative patients [29]. The most common biofilm form-
ing organisms are S.aureus and P.aeruginosa. S.aureus
biofilm is associated with severe and recalcitrant CRS
[30]. Wormald et al. showed that biofilm forms of S.aur-
eus were able to elicit an intense immune response when
the sinonasal tissue explants were stimulated for 24 h
compared to unstimulated explants [30]. In our study,
we were able demonstrate that the biofilm forms of
S.aureus and P.aeruginosa are both able to induce an
inflammatory response in gram-negative CRS predomin-
ant patients but not in gram-positive predominant pa-
tients or in non-CRS patients by producing RANTES,
which is a potent eosinophil chemotactic agent. Again
the virulent nature of gram-negative bacteria and their
ability to recur could have an impact on the innate
immune response.
The link between biofilms and chronic diseases is well
established. Biofilms are suspected to cause diseases by
using several mechanisms: for example, continuous plank-
tonic cell detachment and the release of endotoxin and
exotoxin are well-documented [31, 32]. Moreover, biofilms
are highly resistant to both host immunity and antibiotics.
Studies estimate that biofilms are able to persist despite
using 100 to 1000 times the concentrations of antibiotics
and biocides that can inhibit planktonic cells [31]. Also,
host immunity cells are not able to eliminate biofilms as
they would in a planktonic infection [31].
Limitation
One of the limitations of this study is the sample size;
however, we consider this study to be a pilot study, since
no similar previous work has been done, especially in
subcategorizing CRS based on the culture result. We
used a simple culture method to detect the predominant
organisms in the sinus. Although one could argue that a
more sophisticated method would have detected more
organisms, we think that the simple culture is still the
most widely used and clinically relevant method in hos-
pital settings.
Conclusion
Our study demonstrates that CRS patients with predom-
inant gram-negative infections produce a higher level of
RANTES in response to different types of bacteria, and
it is possible that this response might participate to the
influx of eosinophilic inflammation in CRSwNP and
CRSsNP patients. This could suggest that the mucosa of
CRS patients with gram-negative infections has a height-
ened innate immune response compared to controls and
to patients with gram-positive infections.
Additional files
Additional file 1: ELISA for RANTES. (DOCX 16.2 kb)
Additional file 2: ELISA for IL-6. (DOCX 13.4 kb)
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